CTT Pharmaceutical Holdings, Inc. is pleased to announce that a peer-reviewed scientific paper has been published in the journal of Drug Delivery and Therapeutics, authored by our scientist Dr.

New Tampa resource explains what to verify before booking a consult-board certification, facility standards, anesthesia planning, and how to assess before‑and‑after consistency. TAMPA, FL / ACCESS ...

Glasgow Caledonian University has secured £2.6 million to lead a major new UK-wide doctoral training programme to spearhead research into oral health and dental disease prevention.Funded by the ...

Marika Murto brings over 20 years of pharmaceutical expertise in product strategy, innovation, and business transformationHer ...

Linus Health, an AI-driven brain health company pioneering early detection of cognitive impairment and personalized intervention, today announced the appointment of former Academy of Family Physicians ...

Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusionAstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union (EU) ...

Enables in vivo delivery of LEU011 harnessing the VivoCell PlatformTM London, UK and Chicago, IL – 15 December 2025 – Leucid Bio (“Leucid” or the "Company"), a privately-held biotechnology ...

The outpatient clinics market is projected to expand at a compound annual growth rate (CAGR) of 8% over the forecast period.

The breast lesion localization devices market is showing consistent expansion, with an estimated compound annual growth rate of approximately 7% over the forecast period. This growth is fueled by the ...

MSF: Ethiopia’s first R21 malaria vaccine rollout, a global first in a refugee camp Addis Ababa – 15 December 2025: Médecins Sans Frontières (MSF) has completed the first full round of R21 malaria ...

German specialist in mixing, dispersing and powder-wetting technologies, is significantly strengthening its operations in India with the opening of a new facility in Bangalore. The expansion, which ...

Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, announces the completion of cohort 2a in the clinical Phase I trial evaluating the drug candidate 177Lu-AKIR001.